MARKET

SILO

SILO

Silo Pharma Inc
NASDAQ
0.3400
-0.0100
-2.86%
Pre Market: 0.3400 0 0.00% 08:00 01/02 EST
OPEN
0.3331
PREV CLOSE
0.3500
HIGH
0.3500
LOW
0.3250
VOLUME
2.10K
TURNOVER
0
52 WEEK HIGH
3.370
52 WEEK LOW
0.3250
MARKET CAP
4.53M
P/E (TTM)
-0.3671
1D
5D
1M
3M
1Y
5Y
1D
Silo Pharma executes LOI with Allucent for Phase 1 development of SPC-15
TipRanks · 12/30/2025 13:35
Silo Pharma Signs Non-Binding Letter Of Intent With Allucent To Offer Clinical Research Services For Two Phase 1 Trials Of SPC-15 Nasal Spray
Benzinga · 12/30/2025 13:07
Silo Pharma Signs LOI with Allucent for Phase 1 SPC-15 Clinical Trials
Reuters · 12/30/2025 13:05
SILO PHARMA EXECUTES LETTER OF INTENT WITH ALLUCENT TO SUPPORT PHASE 1 CLINICAL DEVELOPMENT OF SPC-15
Reuters · 12/30/2025 13:05
Silo Pharma Receives Extended Nasdaq Compliance Grace Period
TipRanks · 12/29/2025 14:28
Silo Pharma Faces Potential Nasdaq Delisting Over Minimum Bid Price Compliance
Reuters · 12/29/2025 14:04
Weekly Report: what happened at SILO last week (1222-1226)?
Weekly Report · 12/29/2025 09:41
Weekly Report: what happened at SILO last week (1215-1219)?
Weekly Report · 12/22/2025 09:41
More
About SILO
Silo Pharma, Inc. is a diversified developmental-stage biopharmaceutical and cryptocurrency treasury company. The Company’s therapeutic focus is on addressing underserved conditions, including stress-induced psychiatric disorders, chronic pain, and central nervous system (CNS) diseases. The Company’s portfolio includes programs, such as for PTSD, SP-26 for fibromyalgia and chronic pain, and preclinical assets targeting Alzheimer’s disease and multiple sclerosis. Its lead product candidate, SPC-15, is designed as a novel serotonin 4 (5-HT4) receptor agonist that utilizes biomarkers for treatment of stress-induced psychiatric disorders such as PTSD and anxiety disorders. SPC-14 targets glutamate receptor NDMAR and serotonin 5-HT4 to address cognitive and neuropsychiatric symptoms in Alzheimer’s disease. SPU-16 is a candidate targeting central nervous system (CNS) disorders, with an initial indication for multiple sclerosis.

Webull offers Silo Pharma Inc stock information, including NASDAQ: SILO real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, SILO stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading SILO stock methods without spending real money on the virtual paper trading platform.